Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.

IF 2.4 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2025-07-17 DOI:10.1007/s00277-025-06510-y

Laura Cailly, Wayne-Corentin Lambert, Jean-Richard Eveillard, Brigitte Pan-Petesch, Laura Herbreteau, Laetitia Rio, Lanig Civi, Adrian Tempescul, Florence Dalbies, Hussam Saad, Cristina Bagacean, Marie-Anne Couturier, Gaelle Guillerm, Eric Lippert, Jean-Christophe Ianotto

{"title":"Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.","authors":"Laura Cailly, Wayne-Corentin Lambert, Jean-Richard Eveillard, Brigitte Pan-Petesch, Laura Herbreteau, Laetitia Rio, Lanig Civi, Adrian Tempescul, Florence Dalbies, Hussam Saad, Cristina Bagacean, Marie-Anne Couturier, Gaelle Guillerm, Eric Lippert, Jean-Christophe Ianotto","doi":"10.1007/s00277-025-06510-y","DOIUrl":null,"url":null,"abstract":"<p><p>Between March to December 2024, we observed a PEG-IFNα2a shortage in France for MPN patients. We identified and followed 90 patients from our center and observed 80% of difficulties obtaining the drug, and 61 patients among all (67.8%) did not receive their prescribed drug on time (impacted group). Twenty-one patients need to reduce the dosage of PEG-IFNα2a and 27 stopped the drug. Ten clinical events were identified with nine in the impacted group (p=0.04). No hematological or only partial responses were more frequent in the impacted group (p=0.01). The allelic burden variations were also studied during this period; 17 patients obtained a VAF <10%. Eight patients stopped the drug because of VAF <4% and remained with molecular response. Three-quarters of the patients experimented with psychological and financial impacts of shortage. This study is the first one to explore a shortage of cytoreductive drugs happened in MPN. Much informations will be helpful for clinicians.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-025-06510-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Between March to December 2024, we observed a PEG-IFNα2a shortage in France for MPN patients. We identified and followed 90 patients from our center and observed 80% of difficulties obtaining the drug, and 61 patients among all (67.8%) did not receive their prescribed drug on time (impacted group). Twenty-one patients need to reduce the dosage of PEG-IFNα2a and 27 stopped the drug. Ten clinical events were identified with nine in the impacted group (p=0.04). No hematological or only partial responses were more frequent in the impacted group (p=0.01). The allelic burden variations were also studied during this period; 17 patients obtained a VAF <10%. Eight patients stopped the drug because of VAF <4% and remained with molecular response. Three-quarters of the patients experimented with psychological and financial impacts of shortage. This study is the first one to explore a shortage of cytoreductive drugs happened in MPN. Much informations will be helpful for clinicians.

查看原文本刊更多论文

PEG-IFNα2a缺乏的后果和影响：来自MPN法国中心的初步经验。

在2024年3月至12月期间，我们观察到法国MPN患者的PEG-IFNα2a短缺。我们对本中心90例患者进行了识别和随访，观察到80%的患者难以获得药物，其中61例（67.8%）患者未能按时获得处方药物（影响组）。21例患者需要减少PEG-IFNα2a的剂量，27例患者停药。临床事件10例，其中阻生组9例（p=0.04）。阻生组无血液学反应或部分反应更常见（p=0.01）。研究了这一时期的等位基因负荷变化；17例患者获得VAF

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.